Bumpus Namandje
SEC Form 4 insider trading activity
Bumpus Namandje has filed 2 SEC Form 4 filings (3 transaction rows) across 1 company, with disclosures dating back to 2026. 2 of those filings fall inside the rolling window. Most recent filing: Jun 22, 2026.
On the most recent filing, Bumpus Namandje is listed as Director at RECURSION PHARMACEUTICALS, INC. Inside the rolling window, Bumpus Namandje reported no open-market purchases and 2 open-market sales totaling $28K in RXRX. The largest disclosed transaction in the window is a sale of 4,386 RXRX shares on Jun 3, 2026, worth $16K.
Companies traded
Other insiders at RXRX
Insider Buying
$0
reported purchases (SEC code P)
Insider Selling
$28K
reported sales (SEC code S)
Companies
1
in the rolling window
Frequently asked questions
How many SEC Form 4 filings has Bumpus Namandje made?
Bumpus Namandje has filed 2 SEC Form 4 filings (3 transaction rows) across 1 company since 2026.
Which companies does Bumpus Namandje trade?
Bumpus Namandje has filed SEC Form 4 disclosures for 1 company, including RXRX.
When was Bumpus Namandje's most recent SEC Form 4 filing?
Bumpus Namandje's most recent SEC Form 4 filing on Tracefour is dated Jun 22, 2026.
What is Bumpus Namandje's total buy and sell value in the current window?
Inside the rolling retention window, Bumpus Namandje bought $0 and sold $28K based on SEC Form 4 filings.
What was Bumpus Namandje's largest disclosed transaction?
The largest disclosed transaction in the current window is a sale of 4,386 RXRX shares on 2026-06-03, worth $16K, per SEC Form 4 filings.